Within this context, there are a variety of molecular substrates that regulate synaptic scaling, and which show altered expression patterns in AD, that could be considered as treatment targets, for example MSK1, PSD-95, BDNF, Arc, Calcineurin, CaMK4 and Cdk5 (for reviews see [168]). The gene discussed is RPS6KA5; the disease is Alzheimer disease.